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DObjective: The optimal management of mitral regurgitation (MR) in patients with cardiomyopathy has been
controversial. Minimally invasive fibrillating mitral valve replacement (mini-MVR) might limit postoperative
morbidity and mortality by minimizing recurrent MR. We hypothesized that mini-MVR with complete
chordal sparing would offer low mortality and halt left ventricular (LV) remodeling in patients with severe
cardiomyopathy and severe MR.
Methods: From January 2006 to August 2009, 65 patients with an LV ejection fraction (LVEF) of 35%
underwent mini-MVR. The demographic, echocardiographic, and clinical outcomes were analyzed.
Results: The operative mortality compared with the Society of Thoracic Surgeons-predicted mortality was
6.2% versus 6.6%. It was 5.6% versus 7.4% for patients with an LVEF of 20% and 8.3% versus 17.9%
among patients with a Society of Thoracic Surgeons-predicted mortality of 10%. At a median follow-up of
17 months, no recurrent MR or change in the LV dimensions or LVEF had developed, but the right ventricular
systolic pressure had decreased (P¼ .02). At the first postoperative visit and latest follow-up visit, the New York
Heart Association class had decreased from 3.0  0.6 to 1.7  0.7 and 2.0  1.0, respectively (P<.0001 for
both). Patients with an LVEF of 20% and LV end-diastolic diameter of 6.5 cm were more likely to meet
a composite of death, transplantation, or LV assist device insertion (P ¼ .046).
Conclusions: Our results have shown that mini-MVR is safe in patients with advanced cardiomyopathy and
resulted in no recurrent MR, stabilization of the LVEF and LV dimensions, and a decrease in right ventricular
systolic pressure. This mini-MVR technique can be used to address severe MR in patients with advanced
cardiomyopathy. (J Thorac Cardiovasc Surg 2014;148:2045-51)Supplemental material is available online.
The optimal treatment of patients with advanced heart
failure and severe mitral regurgitation (MR) has been
controversial. Up to 50% of patients with chronic heart
failure will have significant MR, and worsening severity
has conferred a proportional decrease in survival.1
Decreasing the severity of MR has been shown to decrease
congestive heart failure symptoms and improve patients’
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has been established, the relative superiority among MV
annuloplasty, repair, and replacement has remained an
open question.
In early studies, MV replacement (MVR) was associated
with greater surgical risk compared with MV repair.
However, the surgical outcomes might be similar in
high-risk populationswith advanced heart failure.3 In patients
with functional MR from cardiomyopathy, the recurrence of
moderate or greater MR has approached 30% within 1 year
after MV repair.4,5 This could explain, in part, the lack of
survival benefit for patients with advanced cardiomyopathy
undergoing MV repair and annuloplasty.6
We have adopted a technique for MVR with
anterior/posterior chordal sparing through a 5-cm right
anterolateral thoracotomy without aortic crossclamping
(mini-MVR). Previous work by our group has shown that
this technique is associated with low surgical mortality in
patients with severe MR and a wide range of left ventricular
(LV) function.7 In patients with LV dysfunction and severe
MR, combining a minimally invasive approach with
preservation of the subvalvular apparatus during MVRdiovascular Surgery c Volume 148, Number 5 2045
Abbreviations and Acronyms
LV ¼ left ventricular
LVEF ¼ LV ejection fraction
mini-MVR ¼ minimally invasive fibrillating mitral
valve replacement
MR ¼ mitral regurgitation
MV ¼ mitral valve
MVA ¼ MVannuloplasty
MVR ¼ MV replacement
NYHA ¼ New York Heart Association
RV ¼ right ventricular
STS ¼ Society of Thoracic Surgeons
Acquired Cardiovascular Disease Brittain et al
A
C
Dmight minimize adverse LV remodeling and maximize
postoperative functional status. We hypothesized that
this technique would be durable and offer favorable
perioperative morbidity and mortality compared with the
Society of Thoracic Surgeons-predicted rates in patients
with an LV ejection fraction (LVEF) of 35% and
advanced heart failure.METHODS
Study Design
The Vanderbilt University institutional review board approved the
present study (institutional review board no. 101741). From January
2006 to August 2009, 65 patients with an LVEF of 35% underwent
anterior/posterior chordal sparing mini-MVR under cold fibrillatory arrest
and without aortic crossclamping. All patients had symptomatic heart
failure with at least moderate (>2þ) MR. Operative mortality was defined
as death within 30 days of the surgical procedure. In-hospital mortality was
defined as death during the same admission as the surgical procedure.
All causes of MR were included. Patients with endocarditis, congenital
disease, or concomitant mitral stenosis were excluded from the analysis.
Selection Rationale
The procedure has become our standard approach for MV surgery in
patients with or without cardiomyopathy in the absence of concomitant
aortic valve disease or coronary artery disease involving the left main or
left anterior descending artery. This approach was also contraindicated if
the aortic insufficiency were greater than moderate. For patients with
concomitant coronary artery disease and mitral disease, if a lesion in
the left circumflex artery or right coronary artery were amenable to
percutaneous coronary intervention, we stented the coronary artery lesion
and then performed minimally invasive valve surgery. For coronary artery
disease involving the left main or left anterior descending artery, this
approach was contraindicated.
Surgical Technique
The surgical technique has been previously described.7 In brief, after
induction of general anesthesia and endotracheal intubation, a pacing
Swan-Ganz pulmonary artery catheter, a transesophageal echocardiogram
probe and external defibrillator (Zoll Medical Corp, Chelmsford, Mass)
were placed. A 5-cm right anterolateral thoracotomy was performed
through the fourth intercostal space. If the descending aorta was free of
atheroma greater than grade III, the femoral artery was cannulated
using a 16F or 18F straight cannula (Edwards Lifesciences, Irvine, Calif).
Otherwise, axillary cannulation was preferred.2046 The Journal of Thoracic and Cardiovascular SurThe femoral vein was cannulated with a 28F venous return cannula
(Cardiovations, Inc, Calif), and the patients were placed on cardiopulmo-
nary bypass with vacuum-assisted drainage. Fibrillatory arrest was induced
by cooling the patients to 28C. The left atriumwas immediately opened in
the atrioventricular groove. Carbon dioxide was continuously insufflated
into the chest throughout the procedure to displace the intracardiac air,
and left atrial sump suction was used to maintain a clear operative field.
The anterior and posterior leaflet chordae were preserved in all patients
included in the present study. The anterior leaflet was divided in the middle,
and the 2 created edges were reattached to the annulus, thus, reattaching all
the chordal support of the anterior leaflet. Toward the end of the procedure,
the patient was rewarmed, and the left atrial appendage was oversewn.
Careful examination for air using transesophageal echocardiography with
the patient in a deep Trendelenburg position was performed. Strict air
evacuation using carbon dioxide and de-airing using a LV vent through
the valve was performed before complete rewarming and defibrillation.
Therefore, if the patient spontaneously cardioverted, the MV was kept
incompetent to prevent air ejection. The MV was kept incompetent, and
cardioversion was accomplished using the Zoll pads (Zoll Medical Corp)
before completing left atrial closure.
Echocardiographic Analysis
Echocardiograms were performed at Vanderbilt University using
either an iE33 (Philips, Amsterdam, The Netherlands) or Acuson
(Siemens, Mountain View, Calif) cart as a part of routine clinical care.
The echocardiographic data were reviewed by 2 experienced physicians
(L.A.M. and K.B.C.). Quantitative analysis was performed on echo-
cardiograms of adequate quality according to the guidelines published by
the American Society of Echocardiography.8 The LV volumes were
measured using the method-of-discs from the orthogonal apical views.
The severity ofMRwas graded using the proximal isovelocity areamethod,
vena contracta, and pulmonary vein Doppler characteristics. The right
ventricular (RV) systolic pressure was estimated using the simplified
Bernoulli equation according to the American Society of Echocardiogra-
phy guidelines.
Statistical Analysis
Continuous data are expressed as the mean  standard deviation. The
unpaired, 2-tailed Student t test and Mann-Whitney U test were used to
measure differences in continuous variables between the groups according
to the specifications. Categorical variables were compared between groups
using the c2 test. Event-free survival was defined as freedom from a
combined endpoint of death, heart transplantation or transplant listing, or
LV assist device insertion. Survival curves were constructed using the
Kaplan-Meier method, and survival differences were compared using the
log-rank test. Logistic regression analysis was used to estimate the effect
of various parameters. The Society of Thoracic Surgeons (STS) estimated
rates of mortality and morbidity were calculated using the online STS
calculator.9 From previous work from our group, we prespecified the
subgroup analysis in the high-risk group with either an LVEF of 20%
or STS-predicted operative mortality of >10%.10 The observed and
predicted mortality rates were compared using the Wilcoxon signed rank
test. Statistical analyses were performed using Prism, version 5.0, software
(Graph Pad Software, Inc, La Jolla, Calif) and the Statistical Package for
Social Sciences, version 20, software (SPSS, Inc, Chicago, Ill).RESULTS
Patients
A total of 65 patients (74% male, 26% female), with a
mean age of 65  10 years, underwent mini-MVR.
Of the 65 patients, 6 (9%) underwent concurrent
tricuspid valve repair or replacement and 10 (15%)gery c November 2014
TABLE 1. Preoperative demographics and comorbidities for entire
cohort (n ¼ 65)
Variable Value
Age (y) 64.9  10.4
Female gender 17 (26)
Medications (%)
b-Blocker 80
ACEI/ARB 74
MRA 45
Diuretic 86
Digoxin 49
NYHA class 3.0  0.6
II 12 (19)
III 38 (58)
IV 15 (23)
Rhythm (%)
Sinus rhythm 49
Atrial fibrillation 22
Paced 26
Other 3
Preoperative biventricular pacing (%) 12
QRS duration (ms), excluding paced patients 115  25
Brain natriuretic peptide level (pg/mL) (n ¼ 24) 935  925
Creatinine  1.5 mg/dL 13 (20)
Hemodialysis 1 (1.5)
COPD 19 (29)
Diabetes 28 (43)
Hypertension 48 (74)
Dyslipidemia 19 (29)
Cardiogenic shock 1 (1.5)
Previous CVA 13 (20)
Urgent surgery 23 (35)
Emergent surgery 1 (2)
Concomitant CAD 46 (71)
Unstable angina 6 (9.0)
CHF 53 (82)
Inotropic support 4 (6.0)
Low cardiac output syndrome 1 (1.5)
Preoperative right ventricular dysfunction 16 (25)
Preoperative intra-aortic balloon pump use 1 (1.5)
Previous cardiac operation
Isolated coronary artery bypass grafting 32 (49)
MV surgery 3 (4.5)
Other 3 (4.5)
Previous percutaneous coronary intervention (6 h) 10 (1)
Data presented as mean  standard deviation, n (%), or %. ACEI, Angiotensin-
converting enzyme inhibitor; ARB, angiotensin receptor blocker;MRA, mineralocor-
ticoid receptor antagonist; NYHA, New York Heart Association; COPD, chronic
obstructive pulmonary disease; CVA, cerebrovascular accident; CAD, coronary artery
disease; CHF, congestive heart failure; MV, mitral valve.
TABLE 2. Operative characteristics and postoperative complications
Variable Value
Mitral regurgitation etiology
Ischemic 43 (66)
Functional 10 (15)
Myxomatous 9 (14)
Other 3 (5)
Prosthesis type
Bioprosthesis 62 (95)
Mechanical 3 (5)
Fibrillatory arrest time (min) 86.9  24.1
Cardiopulmonary bypass time (min) 120.4  33.0
Operating room time (min) 274.2  54.6
Intubation duration (h) 17.3  19.6
Intensive care unit stay (d) 4.3  3.7
Length of stay (d) 8.6  4.1
Total transfusions (U) 2.0  3.0
Postoperative low cardiac output syndrome 5 (8)
New myocardial infarction 1 (2)
Reoperation for bleeding 2 (3)
Postoperative CVA 1 (2)
Postoperative acute renal failure 2 (3)
Renal failure requiring hemodialysis 0 (0)
Postoperative TIA 1 (2)
Tracheostomy 1 (2)
New atrial fibrillation 8 (12)
Wound infection 0 (0)
Permanent pacemaker implantation 7 (11)
In-hospital mortality 1 (2)
Data presented as mean  standard deviation or n (%). CVA, Cerebrovascular
accident; TIA, transient ischemic attack.
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hours of mini-MVR (hybrid revascularization). The clinical
characteristics, including comorbidities, are listed in
Table 1. The acuity of the study cohort was high, as
evidenced by a mean preoperative New York Heart
Association (NYHA) class of 3.0  0.6 and a high
prevalence of diabetes mellitus, chronic renal disease,The Journal of Thoracic and Carcerebrovascular disease, and coronary artery disease.
In addition, 37% of the operations were performed under
urgent (n ¼ 23) or emergent (n ¼ 1) circumstances. Urgent
status was defined as a patient presenting with heart failure
requiring hospitalization and undergoing MVR in the same
admission.
The operative characteristics and postoperative compli-
cations are listed in Table 2. Most patients (81%) had
secondary MR due to ischemic cardiomyopathy or dilated
cardiomyopathy. The 9 patients (14%) with myxomatous
MV disease underwent MVR because the MV anatomy
was not amenable to MV repair. All patients had undergone
an attempt at MV repair first and were believed to require
MVR after failure to reconstruct the MV competency. No
perivalvular leak was found in any patient immediately
postoperatively using transesophageal echocardiography.
Two patients (3%) developed postoperative renal failure,
and 1 patient (1.5%) experienced a cerebrovascular
accident. The in-hospital mortality was 2.0%, and the
operative (30-day) mortality was 6%.
The NYHA class at the first postoperative visit
(median, 1.5 months; interquartile range 1.1-1.8) decreased
from 3.0  0.6 to 1.7  0.7 (P< .0001). At the latest
available follow-up (median, 40.0 months; interquartilediovascular Surgery c Volume 148, Number 5 2047
TABLE 3. Echocardiographic measurements
Variable Preoperative Postoperative
P
value
LVEF (%) (n ¼ 44) 24.8  7.0
(range 8-35)
25.3  13.8 .84
LVEDD (cm) (n ¼ 36) 6.4  0.9 6.2  1.1 .19
LVESD (cm) (n ¼ 36) 5.4  0.9 5.3  1.4 .62
LV mass index (g/m2)
(n ¼ 36)
156.5  43.0 145.5  49.7 .13
RVSP (mm Hg) (n ¼ 25) 49.9  16.2 41.7  13.7 .02
RV size (cm) (n ¼ 19) 3.5  0.9 3.4  0.7 .28
Left atrial size (cm)
(n ¼ 34)
5.0  0.8 4.8  0.7 .07
Data presented as mean  standard deviation. LVEF, Left ventricular ejection
fraction; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular
end-systolic dimension; LV, left ventricular; RVSP, right ventricular systolic pressure;
RV, right ventricular.
FIGURE 1. Observed versus predicted operative mortality for the entire
cohort of patients, for patients with a left ventricular ejection fraction
(EF) of 20% and for patients with Society of Thoracic Surgeons (STS)
predicted mortality of 10%. Using the Wilcoxon signed rank test,
the observed operative survival was significantly better than the
STS-predicted survival for the entire cohort (P< .001), patients with a
left ventricular EF of 20% (P ¼ .001), and patients with
STS-predicted mortality of 10% (P ¼ .03).
FIGURE 2. Freedom from death or transplantation in patients with a left
ventricular ejection fraction of 20% and left ventricular end-diastolic
diameter of 6.5 cm.
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 0.7 to 2.0  1.0 (P<.0001).
Echocardiographic Data
The preoperative echocardiographic data are listed in
Table 3. The mean preoperative LVEF was 25%  7%,
and 20 patients (31%) had an LVEF of 20%.
Postoperative echocardiographic data were available for a
subset of 36 patients (Table 3). At a mean follow-up of
19.1  16.4 months, no difference was found in the
LVEF, LVend-diastolic diameter, LVend-systolic diameter,
or LVmass index. A significant decrease occurred in the RV
systolic pressure from 49.9  16.2 mm Hg to 41.7  13.7
mm Hg (P ¼ .02), with a trend found toward a decrease
in the left atrial dimension (P ¼ .07). The demographic,
clinical, and preoperative echocardiographic data for
patients who did and did not undergo follow-up echocar-
diography were compared. No significant differences
were found in the preoperative NYHA class, LV size or
function, or RV systolic pressure (Table E1).
At a mean follow-up of 17 months, none of the 36
patients had recurrent MR graded greater than trace, and
no perivalvular leaks were present. The presence of
pulmonary hypertension graded moderate or greater
decreased from 53% to 19% (P<.001).
Mortality and Morbidity Analysis
After a median follow-up period of 35.2 months
(interquartile range, 25.5-50.3), 25 patients (36%) met the
composite endpoint of death (n ¼ 21), LV assist device
insertion, heart transplantation, or United Network for
Organ Sharing listing for heart transplantation. The
operative mortality (<30 days) was 6% (n ¼ 4). Four
patients underwent heart transplantation or United Network
for Organ Sharing listing during the study period.
One patient (1.5%) each required preoperative and
intraoperative balloon pump support.2048 The Journal of Thoracic and Cardiovascular SurThe observed operative mortality for the entire cohort
compared with the STS-predicted mortality was 6.2%
versus 6.6% (P< .001; Figure 1). The observed versus
expected operative mortality was 5.6% versus 7.4% for
patients with an LVEF of 20% (P ¼ .001) and 8.3%
versus 17.9% for patients with an STS-predicted mortality
of 10% (P ¼ .03).
The 7 patients with an LVEF of 20% and LV
end-diastolic diameter of 6.5 cm were significantly
more likely to meet the composite endpoint and thus
represented a particularly high-risk group of patients for
this procedure (log-rank, 0.046; Figure 2). Logistic
regression analysis was used to test the effect of various
factors on the composite outcome. On univariate analysis,
the odds ratio for the composite outcome was 2.0 for
LV end-systolic diameter (P ¼ .03), 5.1 for creatinine
>1.5 mg/dL (P ¼ .02), 7.7 for NYHA class III (P ¼ .06),
and 14.7 for NYHA class IV (P ¼ .02). Although the small
sample size (n ¼ 65 patients) limited our ability to use a
multivariate approach, the results yielded evidence
supporting the effect of these measures on the composite
outcome.gery c November 2014
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DDISCUSSION
Major Findings
The results of our study have shown that mini-MVR with
bileaflet chordal sparing using a fibrillating technique is
safe and provides durable freedom from recurrent MR in
patients with advanced cardiomyopathy. This approach also
conferred a sustained improvement in NYHA functional
class in patients with advanced cardiomyopathy. The opera-
tive mortality in our cohort was lower than that predicted
by the STS risk calculator. This was especially apparent
when the STS estimated risk was 10%. As expected, at a
mean follow-up period of 17 months, no patient had MR
graded greater than trace, and no patient had a perivalvular
leak. No progression of LV dilation or decrement in LVEF
was found, and the stabilization of LV size and function
was accompanied by a significant decrease in the RV systolic
pressure, estimated using Doppler echocardiography.MV Surgery in Advanced Heart Failure
The best approach to MR in patients with severe LV
dysfunction is unknown. Bolling and colleagues11 pub-
lished the first report of clinical and echocardiographic
improvement after MV surgery in patients with advanced
cardiomyopathy. They described a cohort of 16 patients
undergoing MV annuloplasty (MVA) with preservation
of the chordal apparatus. At 8 months of follow-up,
the NYHA functional class had decreased (3.9  0.3 to
1.7  0.5, P<.001) in surviving patients, and the 1-year
survival was 75%, with no operative deaths. These findings
were later validated by the same group in an expanded
cohort of 48 patients, although the rate of recurrent MR at
follow-up was not reported.12 In a large, retrospective study,
Wu and colleagues6 compared the outcomes between
patients with MR and severe LV dysfunction who had
undergone MVA (surgical management) and medical
management in operative candidates. They found no
survival benefit for surgical management. Recent data
published by the Mayo Clinic have shown that the specifics
of MV repair versus MVR did not seem to affect survival in
this group of patients, and patient-associated comorbidities
seemed to be themajor driver of survival for this population.
Another large study of patients undergoing MV surgery for
ischemic MR and associated ischemic cardiomyopathy
found that the reoperation rates were greater after MV
repair, but the valve-related complications were similar
between MVR and MV repair.13 However, they found no
survival benefits between MVR and MV repair in
propensity-matched populations.13Remodeling After MV Surgery in Advanced Heart
Failure
The effect of the MV surgical technique on LV
remodeling is also unclear. In secondary MR from dilatedThe Journal of Thoracic and Carcardiomyopathy, the cardiomyopathic process will persist
after MV surgery, resulting in progressive LV remodeling,
additional dilation of the mitral annulus, and an increase
in MR. This results in a subsequent increased incidence of
recurrent MR. Even with undersizing during MV repair,
the posterior leaflet will be tethered, and postoperative
MV competence after annuloplasty will continue to be
altered. Restricting annular dilatation by MVR might,
therefore, limit recurrent MR, perhaps promoting positive
long-term remodeling in patients with a very low LVEF.
Although MVA will eliminate or significantly reduce MR
at surgery in most patients, the rate of recurrent MR has
been high at medium- to long-term follow-up.4,14,15
McGee and colleagues5 found that although high-grade
(3 or 4þ) MRwas uncommon immediately postoperatively,
the degree ofMR increased rapidly during the first 6 months
and then became relatively stable. Overall, 28% of patients
had grade 3 or 4þ MR at 6 months of follow-up. Others
have reported an incidence of moderate or greater MR of
29% at 3 years of follow-up after MV repair, and the degree
of recurrent MR correlated with the decline in postoperative
LVEF in their cohort.16 The high rates of recurrent MR after
MV repair and/or MVA might have contributed to the
failure of these procedures to provide a survival benefit.
Therefore, MVR, which in our cohort was associated with
no recurrent MR, could represent an attractive alternative
to MV repair and/or MVA in this population. MVR can
provide a durable solution to the treatment of secondary
MR, although the initial attempts that did not preserve the
chordal apparatus were associated with a postoperative
decline in LV systolic function.17 However, conservation
of the subvalvular apparatus during MVR has been
associated with improved postoperative LVEF and a
decreased LV volume.18
Outcomes After MV Surgery
Several studies have shown greater operative mortality
after MVR than after MV repair.19-21 Our operative
mortality and postoperative morbidity compared favorably
with the STS-predicted rates and rates from recent studies
comparing the outcomes after MV repair and MVR.19,20
Other recent studies have suggested that survival in
high-risk populations such as ours might be similar between
MVR and MV repair.13,15,20 We believe that preservation of
both leaflet chordae is essential to maintaining the LV
geometry and function. Moreover, avoiding aortic
crossclamping and administration of cardioplegia is
essential, especially in patients with an LVEF<20% and
poor RV function. Although speculative, we believe
hypothermic fibrillatory arrest has proved to be a superior
myocardial protection method for patients with severe LV
or RV dysfunction. This technique keeps the heart
decompressed by opening the left atrium immediately on
fibrillation. Thus, the left ventricle will not be stressed bydiovascular Surgery c Volume 148, Number 5 2049
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which will increase the intracardiac pressure and reduce
the coronary perfusion pressure. Fibrillatory arrest has
been associated with lower lactate accumulation and
greater coronary flow compared with crossclamping with
cardioplegic arrest and might confer added myocardial
protection.22 However, Gammie and colleageus23 recently
showed in a large study of less-invasive MV operations
that fibrillating heart techniques were associated with a
threefold greater risk of perioperative stroke. However,
our group recently described a cohort of 504 patients
undergoing MV surgery using the fibrillating technique,
and we did not observe a significant risk of stroke. Among
the highest risk patients in that study (STS-predicted
mortality  10%), only 1 of 47 (2%) experienced a
perioperative stroke.10
The postoperative functional status is perhaps the most
important metric of operative success. Mini-MVR in our
cohort resulted in a significant decrease in NYHA class at
both short- and intermediate-term follow-up. Studies
examining NYHA functional class after MV repair have
shown similar improvements in postoperative functional
status.12,24 To our knowledge, our study represents the
longest follow-upNYHA functional class data of any cohort
of patients with advanced heart failure after mini-MVR.
Given the durability of the mini-MVR technique in
eliminating MR, sustained functional class improvement
might be more likely after MVR than after MV repair.
No randomized trial data exist comparing surgical versus
medical management for patients with LV dysfunction
and severe MR. In patients undergoing MV surgery,
no randomized data have compared surgical techniques,
although data from large randomized studies will be
forthcoming from the Cardiothoracic Surgery Network.
Our data have demonstrated that a minimally invasive
fibrillating surgical approach to MVR can be performed
safely, with favorable long-term outcomes with respect to
functional status and LV remodeling. Our results of
stabilization of LVEF and LV dimensions after
chordal-sparing MVR were similar to those from earlier
studies25 and have expanded on those data by showing
that this can be accomplished safely in a large cohort of
patients with severe LV dysfunction.
Our cohort was too small to draw conclusions about the
efficacy of this technique for the different etiologies of
MV disease or compared with other techniques. However,
these data warrant prospective evaluation of this technique
and consideration of a randomized trial comparing this
technique and conventional MV repair in patients with
advanced heart failure.
Study Limitations
Our study was limited by its single-center experience and
relatively small sample size; however, this is the largest2050 The Journal of Thoracic and Cardiovascular Surcardiomyopathy cohort reported using this surgical
technique. To maximize operative success, this procedure
should be performed by surgeons who have had specific
training in this technique. However, once this training has
been obtained, it can be performed in a wide variety of
clinical settings. No multivariate analysis was feasible
owing to the low number of events. The decision to treat
these patients surgically was made by the individual sur-
geon based on clinical judgment. Other patients might
have been deemed nonoperative candidates, for whom we
do not have outcome data. However, our cohort included
patients with significant comorbidities. Only a subset of
our cohort had postoperative echocardiographic data
available. To address the potential for selection bias in
this group, we showed that no differences were present in
the preoperative functional class or echocardiographic
parameters between those who did and did not undergo
repeat echocardiography.
Our series did not include a control group of patients who
underwent MV repair because MVR using a minimally
invasive fibrillating approach was the preferred treatment
of patients with severe functional and ischemic MR and
advanced cardiomyopathy for whom MV surgery is
indicated. We recognize this as a significant limitation of
our study; however, our data suggest that mini-MVR results
in no recurrent MR and outcomes similar to those of other
series of high-risk patients undergoing MV repair. The
use of bioprostheses was heavily favored in our cohort,
given the relatively limited life expectancy of patients
with advanced cardiomyopathy.
CONCLUSIONS
Our data have shown that fibrillating mini-MVR with
complete chordal sparing can be performed safely in
patients with advanced cardiomyopathy, with favorable
results compared with the published and STS-predicted
rates of operative mortality. In our cohort, this procedure
resulted in no recurrent MR, stabilization of LVEF and
LV dimensions, and a decrease in the RV systolic pressure.
In addition, sustained improvement of 1 functional class
was found at 30 months of follow-up.
Future studies examining the best treatment options for
patients with significant MR and LV dysfunction should
consider this surgical approach as a viable treatment option.
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TABLE E1. Demographics and comorbidities of cohorts with and
without repeat echocardiogram
Variable
Repeat echocardiogram
P valueYes (n ¼ 45) No (n ¼ 20)
Age (y) 63.9  10.9 67.0  9.2 .27
NYHA class
Preoperative 3.0  0.7 3.1  0.4 .56
First postoperative visit 1.8  0.7 1.4  0.5 .04
Latest follow-up visit 2.1  1.0 1.7  0.8 .92
Preoperative LVEF (%) 24.8  6.9 26.3  9.8 .54
Preoperative LVEDD 6.4  0.9 6.5  1.1 .70
Preoperative LVESD 5.4  5.6 5.6  1.2 .60
Preoperative RVSP 50.2  15.3 56.3  18.1 .30
Creatinine  1.5 mg/dL 5 (11) 8 (40) .01
COPD 12 (27) 7 (35) .50
Diabetes 20 (44) 8 (40) .74
Hypertension 32 (71) 16 (80) .45
Previous CVA 11 (24) 2 (10) .18
Urgent/emergent surgery 19 (42) 5 (25) .18
Concomitant CAD 29 (64) 17 (85) .09
CHF 35 (78) 18 (90) .24
Preoperative RV dysfunction 11 (31) 5 (29) .88
Previous cardiac surgery 20 (44) 10 (50) .80
Data presented as mean  standard deviation or n (%). NYHA, New York Heart
Association; LVEF, left ventricular ejection fraction; LVEDD, left ventricular
end-diastolic diameter; LVESD, left ventricular end-systolic diameter; RVSP, right
ventricular systolic pressure; COPD, chronic obstructive pulmonary disease;
CVA, cerebrovascular accident; CAD, coronary artery disease; CHF, congestive heart
failure; RV, right ventricular.
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